A trend towards improved median overall survival (mOS) was noted among the 2 groups but did not reach statistical significance (Group A vs .
← all excerpts
Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia.
1
—
—